Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the
appointment of David A. Roth, M.D., as senior vice president, clinical
development and medical affairs. In this newly created role, Dr. Roth
will have responsibility for the clinical development organization and
clinical operations, and he will also build and oversee the medical
affairs function. Dr. Roth will serve as a member of Infinity’s
executive leadership team and will report to Pedro Santabarbara, M.D.,
Ph.D., the company’s chief medical officer. Dr. Roth brings to Infinity
over 20 years of experience in hematology and oncology research and
development.
“It’s a pleasure to welcome David to Infinity. He holds a distinguished
track record spanning both industry and academia. His appointment
substantially enhances the depth and breadth of Infinity’s hematology
and oncology expertise as we rapidly advance our lead program, IPI-145,
toward late-stage development and potential registration,” stated Dr.
Santabarbara. “David’s experience encompasses both early-stage and
registration-phase programs, and the Infinity team looks forward to his
contributions as we work to advance and expand our pipeline.”
“Infinity’s PI3K-delta,gamma inhibitor, IPI-145, has the potential to
help transform the treatment landscape for patients with hematologic
malignancies, and I am pleased to join Infinity at such an exciting
time,” commented Dr. Roth. “Infinity has a history grounded in science
and academic collaborations, and I’m delighted to be a part of this team
as we strive to bring important new treatment options to patients and
their physicians.”
Dr. Roth joins Infinity following more than ten years with Pfizer Inc.
and Wyeth Pharmaceuticals. At Pfizer, he most recently served as a vice
president in Pfizer’s oncology business unit. Dr. Roth joined Pfizer
from Wyeth, where he held the role of assistant vice president, clinical
research & development and global therapeutic area director of
hematology. While at Pfizer and Wyeth, Dr. Roth contributed to the
successful regulatory approval of several products, including Bosulif®
(bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment
of chronic myelogenous leukemia, Xyntha® and ReFacto AF®
for the treatment of hemophilia A, and BeneFIX® for the
treatment of hemophilia B. Dr. Roth also led the early development of
palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER
positive advanced breast cancer. During his tenure at Pfizer and Wyeth,
Dr. Roth also co-chaired Pfizer’s oncology research and development
board and served on several oncology and hematology R&D leadership teams
and governance committees.
In addition to his extensive industry experience, Dr. Roth is an
accomplished academic researcher and clinical practitioner. He received
his B.S. from the Massachusetts Institute of Technology and his M.D.
from Harvard Medical School in the Harvard-M.I.T. Division of Health
Sciences and Technology where he remains on the Affiliated Faculty.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to
discovering, developing and delivering best-in-class medicines to people
with difficult-to-treat diseases. Infinity combines proven scientific
expertise with a passion for developing novel small molecule drugs that
target emerging disease pathways. Infinity’s programs focused on the
inhibition of phosphoinositide-3-kinase and heat shock protein 90 are
evidence of its innovative approach to drug discovery and development.
For more information on Infinity, please refer to the company’s website
at www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding the company’s
expectations about: the expected responsibilities of Dr. Roth; the
advancement of IPI-145 toward late-stage development and potential
registration; and the therapeutic potential of its PI3K inhibitors. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from the company’s current expectations. For example, there
can be no guarantee that Infinity will initiate clinical trials or
report data in the time frames it has estimated, that any product
candidate Infinity is developing will successfully complete necessary
preclinical and clinical development phases or that development of any
of Infinity’s product candidates will continue. Further, there can be no
guarantee that any positive developments in Infinity’s product portfolio
will result in stock price appreciation. Management’s expectations and,
therefore, any forward-looking statements in this press release could
also be affected by risks and uncertainties relating to a number of
other factors, including the following: Infinity’s results of clinical
trials and preclinical studies, including subsequent analysis of
existing data and new data received from ongoing and future studies; the
content and timing of decisions made by the U.S. FDA and other
regulatory authorities, investigational review boards at clinical trial
sites and publication review bodies; Infinity’s ability to obtain and
maintain requisite regulatory approvals and to enroll patients in its
clinical trials; unplanned cash requirements and expenditures;
development of agents by Infinity’s competitors for diseases in which
Infinity is currently developing its product candidates; and Infinity’s
ability to obtain, maintain and enforce patent and other intellectual
property protection for any product candidates it is developing. These
and other risks which may impact management’s expectations are described
in greater detail under the caption “Risk Factors” included in
Infinity’s quarterly report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on August 8, 2013, and other filings filed by
Infinity with the SEC. Any forward-looking statements contained in this
press release speak only as of the date hereof, and Infinity expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
Bosulif® and Xyntha® are registered trademarks of
Wyeth LLC. ReFacto AF® and BeneFIX® are registered
trademarks of Genetics Institute, LLC.
Copyright Business Wire 2013